Lactose in Medications and the Rest of the Label Nobody Reads

A low-lactose diet sheet can sit on the kitchen counter beside a high-lactose prescription for years, and nothing in a standard chart will flag the conflict. The lab panel is normal. The stool test lists its species. Nobody has read the second half of the label.

Lactose in medications is the easiest place to see the problem, but it is only the first line of a longer list. The video Two-Thirds of Your Pill Is Not the Drug, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, makes the case for reading that list. What follows is the terrain side of it: what the formulation delivers to the gut wall, and why the tests people rely on miss most of it.

Most of the tablet is packaging

A pill is a delivery system, and the drug is often the smallest part. Across the approved oral solid supply, 41.3% of products carry more than 250 mg of inactive ingredients. The heaviest single tablet found was an 80 mg atorvastatin carrying 770 mg of inactive material. The lightest, a 5 mg simvastatin, still carried 50 mg, which was 90% of its mass.

That is the practical opening. Levothyroxine alone comes in 140 distinct formulations from 43 manufacturers. The common tablet contains lactose and aluminum lake dyes. Another version is a soft gel made of water, glycerin and gelatin. Same hormone, same dose, a different package arriving at the small bowel.

How much lactose in medications is enough to matter

Lactose is a filler in 45% of all oral solid dosage forms, and a single pill can carry close to 600 mg. People with severe intolerance can react to less than 200 mg. A common blood pressure and cholesterol trio, amlodipine, simvastatin and losartan, adds up to nearly a gram of lactose a day. More than half of oral medications, 55%, contain at least one FODMAP sugar, the fermentable kind that bloats a sensitive gut.

The same investigators concede that for many patients the lactose in a pill appears too small to cause symptoms, and whether low amounts provoke reactions is still debated. That debate is the reason for a trial of avoidance in one person, run with a physician, not a rule for everybody.

A second national count, from the Portuguese drug supply, found lactose in 62.6% of antiasthmatic drugs and 39% of anti-inflammatories. Those are label counts from one market, not an American pharmacy. The same review flagged something no label shows: cow milk protein is never declared, yet lactose carries a risk of cross-contamination with it.

"Inactive" describes paperwork, not biology

The federal register behind every one of these ingredients has seven data fields: the name, route, dosage form, two identifier codes, and potency amount and unit. There is no field for what the substance does, no safety finding, no daily limit. Inclusion records that something has been used before. It says nothing about your intestine.

When one group tested that assumption against biological targets, 38 inactive ingredients showed 134 activities against 44 targets. The same authors insist most excipients earn their inert label, because most never reach meaningful blood levels. In the gut, though, excipients can reach up to 100 times the concentration of the drug they carry.

The white pigment and a wall that is already cracked

Titanium dioxide makes tablets white. In mice, blocking the tight junctions between gut cells cut its uptake through the villi by 66%, which puts the ordinary absorptive surface, not the lymphoid patches, at the front door. In human post-mortem organs, particles turned up in 7 of 15 livers and 13 of 15 spleens, and at least 51% of the liver titanium was intact particles rather than dissolved metal. Presence was measured. Harm in those donors was not.

What the particles do depends on the terrain they meet. In human intestinal cell cultures they raised permeability. In mice with colitis they made inflammation worse, while healthy mice showed no colon damage. In rats fed dietary-level doses for 100 days, colonic TNF-alpha rose 26% and IL-8 rose 45% while barrier permeability held steady. Particles even reached cell nuclei without breaking DNA. Immune disturbance: supported. Damage to a healthy wall: not shown.

The strongest counterpoint is real. A multicenter trial in people with active Crohn’s disease found a low-microparticle diet added nothing to steroid treatment. Avoidance has never been shown to heal a sick bowel. That trial did not test decades of daily exposure, and a tablet releases its pigment in one concentrated spot rather than spreading it through a meal. For a medicine taken every day for years, I prefer the version without it.

The economics explain why the choice rarely comes up. Europe removed the pigment from food in 2022 and kept it in medicines, where it sits in about ninety-one thousand human products and industry estimated 7 to 12 years to replace it. The incentive favors the manufacturer’s line, and the exposure lands on the patient.

What a stool test cannot tell you about your prescriptions

In a large Dutch cohort, no drug and no number of drugs changed microbial richness. The community was not thinned. It was rearranged. In 4,198 people, polypharmacy produced distinct microbiome structures with less short-chain fatty acid metabolism, and the changes reversed when drugs stopped. The census looks stable while the function shifts.

Measurement itself can mislead. Polyethylene glycol, a laxative and common excipient, was reported in the plasma of 77.4% of 200 healthy adults, but only 41 of those 200 samples cleared the assay’s validated floor. Both numbers are true. Only one was actually measured.

And not every drug pushes the terrain the wrong way. In a double-blind randomized trial in people with newly diagnosed type 2 diabetes, metformin reshaped the gut community, and stool from treated donors improved glucose tolerance in germ-free mice. The goal is not a sterile bag. It is a bag where every compound, active or not, has earned its place.

Running the audit with your physician

Two biological forces are at work, contact with the lining and pressure on the microbial community, and one economic one: formulations are chosen for the supply chain, not for your gut. The audit is how you push back on the third.

• Bring the containers and inserts. A drug name tells you nothing about the filler.
• For each daily medicine, ask whether a version exists without lactose, dyes or the pigment.
• If you react to several drugs with unrelated active ingredients, suspect a shared excipient and ask an allergist.
• Log symptoms for two weeks before any formulation switch and four weeks after.
• Change nothing on your own. Every swap goes through the prescriber.

Formulation is one input to the terrain; the rest shows up in why the same treatment heals one person and fails another. Every study above, with its full numbers and limits, is in the Chapter 2 Deep Dive, including what each study does and does not show. Earlier in the series, The Angry Gut, Chapter 1 lays the groundwork. Next comes what heart rate variability does and does not reveal about the gut.

Frequently asked questions

What medications contain lactose?

Lactose is a filler in 45% of oral solid dosage forms, so it turns up across drug classes rather than in one category. The same active drug is often sold in many versions: levothyroxine has 140 formulations, including a soft gel without lactose. Ask your pharmacist to check the inactive ingredients of the exact product you receive. A metabolic audit looks at what else is loading your terrain.

Can I take pills with lactose if I am lactose intolerant?

Often yes, because many pills hold little lactose, and the investigators who counted it say the amounts may be too small to matter for many people. The exception is severe intolerance, which can react below 200 mg, when a single pill can carry close to 600 mg. Work out a trial without it with your physician. See how metabolic optimization reviews the whole picture.

Is titanium dioxide in medication safe?

Regulators disagree about DNA risk, and that argument misses the gut question. Particles cross the intestinal lining in people and persist in organs, and in animals they worsened inflammation only where the barrier was already damaged. For a medicine taken daily for years, a pigment-free version is a reasonable request to your physician. Chronic low-grade inflammation is what ages the terrain.

Can medications change your gut microbiome?

Yes, though usually by rearranging the community rather than emptying it. In large human cohorts, acid blockers, metformin, antibiotics and laxatives showed the strongest links, and taking many drugs together produced its own pattern that reversed when drugs stopped. A randomized trial confirmed that metformin changes the gut community directly. The same microbial shifts can show up as joint pain.

Are inactive ingredients really inactive?

Mostly, at blood levels. When researchers screened them, most excipients showed no binding or toxicity, but 38 showed activity against biological targets. The catch is location: inside the gut they can reach up to 100 times the concentration of the drug itself, so the lining sees exposures the bloodstream never does. A daily anti-inflammatory adds its own long-term burden.

Sources

1. Reker, D., Blum, S. M., Steiger, C., Anger, K. E., Sommer, J. M., Fanikos, J., & Traverso, G. (2019). “Inactive” ingredients in oral medications. Science Translational Medicine, 11(483), eaau6753. https://doi.org/10.1126/scitranslmed.aau6753
2. Pottel, J., Armstrong, D., Zou, L., Fekete, A., Huang, X.-P., Torosyan, H., Bednarczyk, D., Whitebread, S., Bhhatarai, B., Liang, G., Jin, H., Ghaemi, S. N., Slocum, S., Lukacs, K. V., Irwin, J. J., Berg, E. L., Giacomini, K. M., Roth, B. L., Shoichet, B. K., & Urban, L. (2020). The activities of drug inactive ingredients on biological targets. Science, 369(6502), 403–413. https://doi.org/10.1126/science.aaz9906
3. Coméra, C., Cartier, C., Gaultier, E., Catrice, O., Panouille, Q., El Hamdi, S., Tirez, K., Nelissen, I., Théodorou, V., & Houdeau, E. (2020). Jejunal villus absorption and paracellular tight junction permeability are major routes for early intestinal uptake of food-grade TiO2 particles: an in vivo and ex vivo study in mice. Particle and Fibre Toxicology, 17(1), 26. https://doi.org/10.1186/s12989-020-00357-z
4. Heringa, M. B., Peters, R. J. B., Bleys, R. L. A. W., van der Lee, M. K., Tromp, P. C., van Kesteren, P. C. E., van Eijkeren, J. C. H., Undas, A. K., Oomen, A. G., & Bouwmeester, H. (2018). Detection of titanium particles in human liver and spleen and possible health implications. Particle and Fibre Toxicology, 15(1), 15. https://doi.org/10.1186/s12989-018-0251-7
5. Bettini, S., Boutet-Robinet, E., Cartier, C., Coméra, C., Gaultier, E., Dupuy, J., Naud, N., Taché, S., Grysan, P., Reguer, S., Thieriet, N., Réfrégiers, M., Thiaudière, D., Cravedi, J. P., Carrière, M., Audinot, J. N., Pierre, F. H., Guzylack-Piriou, L., & Houdeau, E. (2017). Food-grade TiO2 impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon. Scientific Reports, 7, 40373. https://doi.org/10.1038/srep40373
6. Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., Kurilshikov, A., Wijmenga, C., Zhernakova, A., & Weersma, R. K. (2020). Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications, 11(1), 362. https://doi.org/10.1038/s41467-019-14177-z
7. Nagata, N., Nishijima, S., Miyoshi-Akiyama, T., Kojima, Y., Kimura, M., Aoki, R., Ohsugi, M., Ueki, K., Miki, K., Iwata, E., Hayakawa, K., Ohmagari, N., Oka, S., Mizokami, M., Itoi, T., Kawai, T., Uemura, N., & Hattori, M. (2022). Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology, 163(4), 1038–1052. https://doi.org/10.1053/j.gastro.2022.06.070
8. Figueiredo, A., Auxtero, M. D., Santo, M., Casimiro, A., & Costa, I. M. (2024). Risks of dairy derived excipients in medications for lactose intolerant and cow milk protein allergic patients. Scientific Reports, 14(1), 15631. https://doi.org/10.1038/s41598-024-66380-8
9. Kubesch, K., Lubich, C., Mascher, D., Tangada, S., & Turecek, P. L. (2025). Evaluation of Plasma Polyethylene Glycol (PEG) Levels in a Healthy Adult Population. International Journal of Toxicology, 44(6), 451-457. https://doi.org/10.1177/10915818251371966
10. Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., Xifra, G., Mercader, J. M., Torrents, D., Burcelin, R., Ricart, W., Perkins, R., Fernàndez-Real, J. M., & Bäckhed, F. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine, 23(7), 850-858. https://doi.org/10.1038/nm.4345

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 2 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.